Cephalon Sparlon Additional Pre-Approval Safety Study Recommended To Assess Skin Reaction Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Psychopharmacologic Drugs Advisory Committee rules safety for modafinil product in children with attention deficit/hyperactivity disorder has not been adequately demonstrated.
You may also be interested in...
September Launch Eyed For Cephalon/J&J’s Sparlon
Cephalon plans to launch the attention deficit/hyperactivity disorder treatment Sparlon (modafinil) with partner Johnson & Johnson in September to take advantage of students returning to school, provided FDA approves the product by its Aug. 22 user fee date, Cephalon said
September Launch Eyed For Cephalon/J&J’s Sparlon
Cephalon plans to launch the attention deficit/hyperactivity disorder treatment Sparlon (modafinil) with partner Johnson & Johnson in September to take advantage of students returning to school, provided FDA approves the product by its Aug. 22 user fee date, Cephalon said
Sparlon User Fee Date Extended To August
FDA has extended the user fee date for Cephalon's attention deficit/hyperactivity disorder treatment Sparlon (modafinil) to Aug. 22, the company said April 24